Protagonist Therapeutics Inc PTGX:NASDAQ

Last Price$8.20NASDAQ Previous Close - Last Trade as of 4:00PM ET 7/06/22

Today's Change-0.26(3.07%)
Bid (Size)$7.67 (2)
Ask (Size)$9.37 (2)
Day Low / High$8.14 - 8.72
Volume816.0 K
 

View Biotechnology IndustryPeer Comparison as of 07/06/2022

 

Protagonist Therapeutics Inc ( NASDAQ )

Price: $8.20
Change: -0.26 (3.07%)
Volume: 816.0 K
4:00PM ET 7/06/2022
 
 

BioXcel Therapeutics Inc ( NASDAQ )

Price: $15.85
Change: +1.21 (8.27%)
Volume: 10.00
4:00PM ET 7/06/2022
 
 

Kodiak Sciences Inc ( NASDAQ )

Price: $8.15
Change: +0.12 (1.49%)
Volume: 516.1 K
4:00PM ET 7/06/2022
 
 

ADMA Biologics Inc ( NASDAQ )

Price: $2.18
Change: +0.05 (2.35%)
Volume: 2.0 M
4:00PM ET 7/06/2022
 
 

MiMedx Group Inc ( NASDAQ )

Price: $3.70
Change: -0.06 (1.60%)
Volume: 226.5 K
4:00PM ET 7/06/2022
 

Read more news Recent News

Piper Sandler Adjusts Price Target on Protagonist Therapeutics to $35 From $60, Reiterates Overweight Rating
6:52AM ET 5/18/2022 MT Newswires

Protagonist Therapeutics (PTGX) has an average rating of buy and price targets ranging from $30 to $60, according to analysts polled by Capital IQ. (MT...

--SVB Leerink Adjusts Protagonist Therapeutics' Price Target to $30 from $50, Keeps Outperform Rating
10:00AM ET 5/05/2022 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

Protagonist Therapeutics' Shares Plummet After Reporting Trial Data for Inflammatory Bowel Disease Treatment
2:54PM ET 4/26/2022 MT Newswires

Protagonist Therapeutics (PTGX) shares slumped 53% by Tuesday afternoon, a day after the biopharmaceutical company said a phase 2 study of its proposed...

Top Midday Decliners
1:50PM ET 4/26/2022 MT Newswires

Protagonist Therapeutics (PTGX) shares slumped 49% amid heavy trading after the company reported topline data from a phase 2 trial of PN-943 in ulcerative...

Company Profile

Business DescriptionProtagonist Therapeutics, Inc. a clinical-stage biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address unmet medical needs. Its product pipeline include PTG-300, PTG-200, and PN-943 The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA. View company web site for more details
Address7707 Gateway Boulevard
Newark, California 94560-1160
Phone+1.510.474.0170
Number of Employees64
Recent SEC Filing06/10/2022SC 13G/A
President, Chief Executive Officer & DirectorDinesh V. Patel
Chief Financial Officer & Executive Vice PresidentAsif Ali
Vice President-TechnologyMark L. Smythe
Chief Research & Development Strategy OfficerDavid Y. Liu

Company Highlights

Price Open$8.44
Previous Close$8.20
52 Week Range$6.91 - 50.54
Market Capitalization$399.0 M
Shares Outstanding48.7 M
SectorHealth Technology
IndustryBiotechnology
Next Earnings Announcement08/03/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$2.59
Beta vs. S&P 500N/A
Revenue$30.9 M
Net Profit Margin-261.21%
Return on Equity-38.01%

Analyst Ratings as of 05/19/2022

Buy
6
Overweight
0
Hold
0
Underweight
0
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset